4.8 Letter

Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee

Related references

Note: Only part of the references are listed.
Editorial Material Public, Environmental & Occupational Health

The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac

Peter Arlett et al.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)

Article Biotechnology & Applied Microbiology

The risks of risk aversion in drug regulation

Hans-Georg Eichler et al.

NATURE REVIEWS DRUG DISCOVERY (2013)

Article Pharmacology & Pharmacy

Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval

H-G Eichler et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

News Item Biotechnology & Applied Microbiology

Unleashing the Mini-Sentinel

Asher Mullard

NATURE REVIEWS DRUG DISCOVERY (2012)

Article Public, Environmental & Occupational Health

Evaluation of the effectiveness of risk minimization measures

Luis Prieto et al.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)